Alzheimer's reset in mice
- Researchers reported reversing Alzheimer's-like signs in mice by altering energy balance and testing repurposed cancer drugs. (x.com) (x.com) - Lab reports describe improvements in memory measures and reduced disease markers in those mouse experiments. (x.com) (x.com) - Coverage framed the work as early preclinical research pointing to possible repurposing pathways, not yet human treatments. (x.com) (x.com)
Alzheimer’s slowly destroys brain cells and the support cells around them, eroding memory over years. Two new mouse studies reported that some of those Alzheimer’s-like changes could be pushed backward in animals by restoring brain energy balance or by pairing two repurposed cancer drugs. (cell.com 1) (cell.com 2) In one study, published in *Cell Reports Medicine* in late 2025, researchers linked severe Alzheimer’s pathology in human brains and mouse models to disrupted NAD+ balance, a core molecule cells use to handle energy. In two mouse models with advanced disease, restoring that balance with the compound P7C3-A20 reversed pathology and restored cognitive function, according to the paper summary. (cell.com) (sciencedirect.com) In another study, published in *Cell* on July 21, 2025, scientists at UC San Francisco and Gladstone analyzed single-cell gene activity in human Alzheimer’s brains, then searched for approved drugs that might push those patterns in the opposite direction. They identified letrozole and irinotecan, two cancer drugs, and reported that the combination improved memory and reduced brain degeneration in a mouse model. (ucsf.edu) (gladstone.org) (cell.com) The basic idea in both papers is that Alzheimer’s is not only about amyloid plaques and tau tangles. The studies instead focused on cell systems that keep the brain running day to day: how neurons use fuel, how glial support cells behave, and whether damaged gene networks can be nudged back toward a healthier state. (cell.com 1) (cell.com 2) (psu.edu) That metabolic angle has been building for more than a year. A *Science* paper from August 22, 2024 reported that blocking the enzyme indoleamine-2,3-dioxygenase 1, or IDO1, restored glucose metabolism in astrocytes — support cells that help feed neurons — and rescued memory and brain function in Alzheimer’s models. (psu.edu) (genengnews.com) Researchers are leaning on repurposing because Alzheimer’s drug development has produced few clear wins. Gladstone said its 2025 team screened about 1,300 Food and Drug Administration-approved drugs and also checked millions of electronic medical records for signals that some candidates might be linked to lower Alzheimer’s risk. (gladstone.org) (ucsf.edu) None of this means Alzheimer’s has been reversed in people. The NAD+ work was done in animal models, and the letrozole-irinotecan work was also preclinical, with the human data used to identify targets and check associations rather than to test treatment in patients. (cell.com 1) (cell.com 2) (ucsf.edu) That distinction matters because many Alzheimer’s treatments have looked strong in mice and then failed in human trials. Cancer drugs can also carry serious side effects, so a result in a mouse memory test is not close to a prescription for dementia patients. (gladstone.org) (psu.edu) What these studies add is a sharper map of where to look next: the brain’s fuel system, the relationship between neurons and glia, and whether existing drugs can be combined or adapted for a disease that has resisted one-target fixes. For now, the “reset” happened in mice, and the next test is whether any of those pathways can be moved safely into human trials. (cell.com) (cell.com)
